NCT00009217View on ClinicalTrials.gov

Treatment of Behavioral Symptoms in Alzheimer's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Alzheimer's DiseasePsychosisAgitation
Interventions
DRUG

Haloperidol-Haloperidol

Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks

DRUG

Haloperidol-Placebo

Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT00009217 - Treatment of Behavioral Symptoms in Alzheimer's Disease | Biotech Hunter | Biotech Hunter